Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

1(33%)

Results Posted

0%(0 trials)

Phase Distribution

Ph early_phase_1

33%

Ph phase_2

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Early Phase 1First-in-human

1(33.3%)

Phase 2Efficacy & side effects

2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(1)

Detailed Status

Completed1

Recruiting1

Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Early Phase 11 (33.3%)

Phase 22 (66.7%)

Trials by Status

completed133%

recruiting133%

not_yet_recruiting133%

Recent Activity

1 active trials

Showing 3 of 3

recruitingphase_2

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

NCT07288138

not_yet_recruitingphase_2

MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

NCT07505303

completedearly_phase_1

FTIH of ECC4703 in Healthy Volunteers

NCT05552274

Clinical Trials (3)

Showing 3 of 3 trials

NCT07288138Phase 2

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

Recruiting

NCT07505303Phase 2

MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

Not Yet Recruiting

NCT05552274Early Phase 1

FTIH of ECC4703 in Healthy Volunteers

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3